SWOG clinical trial number
SWOG-7204/7205

Non-Hodgkin's Lymphoma CHOP vs. HOP Combination Chemotherapy for Remission Induction and COP vs. OAP Combination Chemotherapy for Maintenance

Closed
Phase
III
Published
Abbreviated Title
Non-Hodgkin's Lymphoma CHOP vs. HOP Combination Chemotherapy for Remission Induction and COP vs. OAP Combination Chemotherapy for Maintenance
Activated
04/17/1972
Closed
09/10/1974

Research committees

Lymphoma

Publication Information Expand/Collapse

1998

New REAL clinical entities.

RI Fisher;TP Miller;TM Grogan Cancer Journal from Scientific American 4(Suppl.2):S5-S12

1997

Follicular lymphomas: Do histologic subtypes predict outcome?

TP Miller;M LeBlanc;TM Grogan;RI Fisher Hematology/Oncology Clinics of North America 11(5):893-900

1996

Evaluation and management of mantle cell lymphoma.

OW Press;TM Grogan;RI Fisher Advances in Leukemia and Lymphoma 6(1):3-11

Clinical course and therapy of mantle cell lymphoma.

RI Fisher;OW Press;TP Miller;DR Head Principles and Practice of Oncology 10(6):1-7

Mantle-cell lymphoma: Classification and therapeutic implications.

RI Fisher Annals of Oncology 7(Suppl.6):S35-S39

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

BW Dana;S Dahlberg;BN Nathwani;E Chase;C Coltman;TP Miller;RI Fisher Classic Papers and Current Comments 1(2):320-328

1995

A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid b-cell subcategories: A Southwest Oncology Group study.

RI Fisher;S Dahlberg;BN Nathwani;PM Banks;TP Miller;TM Grogan Blood 85(4):1075-1082

1994

A clinical analysis of new indolent lymphoma entities in the revised european american lymphoma (REAL) classification.

RI Fisher;S Dahlberg;TM Grogan ASCO 13:379(#1287)

1993

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

BW Dana;S Dahlberg;BN Nathwani;E Chase;CA Coltman Jr;TP Miller;RI Fisher JCO 11(4):644-651

Treatment of diffuse large-cell lymphoma: A summary of outcome for patients treated by the Southwest Oncology Group.

TP Miller;S Dahlberg Malignant Lymphomas Including Hodgkins Disease 4:53-63

1989

Long-term followup of patients with low grade lymphoma treated with CHOP ( cyclophosphamide, doxorubicin, vincristine, prednisone)-based chemotherapy or chemoimmunotherapy on Southwest Oncology Group studies

B Dana;S Dahlberg;T Miller;S Jones;E Chase;C Coltman, Jr;R Fisher ASCO 8:257(#1001)

Long-term survival of patients with nodular histiocytic (NH),diffuse poorly differentiated lymphocytic (DPDL), diffuse mixed (DM),and diffuse undifferentiated (DU) lymphoma treated with CHOP chemotherapy.

RI Fisher;S Dahlberg;TP Miller;SE Jones;C Coltman, Jr ASCO 8:257(#1003)

1986

CHOP is curative in thirty percent of patients with diffuse largecell lymphoma: A twelve year Southwest Oncology Group followup.

C Coltman, Jr;S Dahlberg;SE Jones;TP Miller;BW Dana;EM McKelvey;RJ Hartsock;DO Dixon ASCO 5:197(#774)

1982

The clinical significance of the morphologic subdivision of diffuse, "Histiocytic" Lymphoma: A study of 162 patients treated by the Southwest Oncology Group

BN Nathwani;DO Dixon;SE Jones;RT Hartsock;JW Rebuck;GE Byrne Jr;WW Sheehan;H Kim;CA Coltman Jr;H Rappaport Blood 60:1068-1074

1981

Lymphoblastic lymphoma: A clinicopathologic study of 95 patients

BN Nathwani;LW Diamond;CD Winberg;H Kim;RM Bearman;JH Glick;SE Jones;RA Gams;NI Nissen;H Rappaport Cancer 48:2347-2357

The chemotherapy of lymphoblastic lymphoma

JB Voakes;SE Jones;EM McKelvey Blood 57:186-188

1979

Combination chemotherapy for mycosis fungoides

P Grozea;S Jones;E McKelvey;CA Coltman;R Fisher;C Haskins Cancer Treat Rep 63(4):647-653

Clinical features of malignant lymphomas

E McKelvey;R Fisher;C Haskins ASCO #C-380

1978

Review of CHOP-HOP combined chemotherapy in malignant lymphoma

McKelvey Placeholder AACR 19: 415

1977

Curability of non-Hodgkin's lymphomas

EM McKelvey;TE Moon Cancer Treat Rep 61:1185-1190

Central nervous system (CNS) lymphoma: clinico- pathologic features and reduced incidence with parenteral cytosine arabinoside

SE Jones;N Hammond;E McKelvey;TS Herman;GE Byrne;JJ Butler Blood 50:194 #359

1976

Hydrosyldaunomycin (adriamycin) combination chemo- therapy in malignant lymphoma

EM McKelvey;JA Gotlieb;HE Wilson;A Haut;RW Talley;R Stephens;M Lane;JF Gamble;SE Jones;PN Grozea;J Gutterman;CA Coltman Jr;TE Moon Cancer 38(4):1484-1493

Cyclophosphamide vs arabinosyl cytosine combination maintenance chemotherapy in malignant lymphoma

EM McKelvey ASCO #C-99

1975

Hydroxyldaunomycin (adriamycin) combination chemo- therapy in non-Hodgkin's lymphoma

EM McKelvey;JA Gottlieb;A Haut;M Lane ASCO #1050

1974

Hydroxyldaunomycin (adriamycin) combination chemo- therapy for advanced non-Hodgkin's lymphoma

EM McKelvey;JU Gutterman;CA Coltman Jr ASH

1973

Hydroxyldaunomycin (adriamycin) combination chemo- therapy for advanced non-Hodgkin's lymphoma

EM McKelvey;JU Gutterman;CA Coltman Jr ASH

1972

Chemotherapy of malignant lymphoma with adriamycin

JA Gottlieb;JU Gutterman;KB McCredie;E Frei III 14th International Congress of Hematology Sao Paulo Brazil, #581